Similarly, the use of IFNγ neutralizing antibodies in IBD patients seems to be inefficient or only partially beneficial for clinical improvement questioning the role of IFNγ in the pathogenesis of IBD (8). This evidence concerns the gene IFNG and inflammatory bowel disease.